Aviceda Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.avicedarx.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Aviceda Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06181227
- Locations
- 🇺🇸
Erie Retina Research, Erie, Pennsylvania, United States
🇺🇸Texas Retina Associates, Dallas, Texas, United States
🇺🇸West Texas Retina Consultants, Wichita Falls, Texas, United States
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Phase 2
Active, not recruiting
- Conditions
- Geographic Atrophy of the MaculaMacular Degeneration
- Interventions
- Drug: Avacincaptad
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Aviceda Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05839041
- Locations
- 🇺🇸
Associated Retina Consultants, Scottsdale, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
News
No news found